AstraZeneca appoints Pam Cheng as Executive Vice President, Operations and IT
AstraZeneca today announced that Pam P. Cheng has joined the Company as Executive Vice President, Operations and IT.
Ämnen: Farmaci
-
-
Tillverkar nedbrytbar plast och renar vatten på sommarlovet
AstraZenecas Sommarforskarskola med spetsplatser för 14 - 17 åringar som vill ha extra utmaningar
-
New real-world data analysis finds no evidence of increased risk of hospitalisation for heart failure with saxagliptin compared with sitagliptin
Study also found no evidence of increased risk of hospitalisation for heart failure for DPP-4 inhibitors compared with sulfonylureas
-
AstraZeneca presents new positive phase III data on triple therapy approach with dapagliflozin, saxagliptin and metformin for type 2 diabetes
Data in oral presentation demonstrate that the investigational combination of dapagliflozin, saxagliptin and metformin resulted in statistically significant reductions in HbA1c in patients uncontrolled on saxagliptin and metformin
-
AstraZeneca to present data demonstrating progress of its comprehensive diabetes portfolio at the American Diabetes Association 75th scientific sessions
AstraZeneca today announced that 86 abstracts reporting results of the company’s research and development in diabetes have been accepted for presentationat the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston, 5-9 June 2015.
-
AstraZeneca updates on immuno-oncology combinations development programme at ASCO 2015
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, provided an update on the progress of their combination-focused immuno-oncology pipeline at an investor science event at the American Society of Clinical Oncology (ASCO) meeting in Chicago on 1 June 2015.
-
AstraZeneca presents positive data on AZD9291 in first-line EGFR mutated lung cancer at ASCO 2015
Over 80% of patients progression free at 9 months in the first-line treatment of advanced non-small cell lung cancer1
AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC). Data showed that 81% (95% confidence interval (CI) 68% to 89%) of p -
AstraZeneca and MedImmune present positive immuno-oncology combination data at ASCO 2015
AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.
Overall, data indicated clinical activity with manageable safety profiles for the anti-programmed cell death ligand 1 (PD-L1) monoclonal -
AstraZeneca and Lilly to collaborate on immuno-oncology combination clinical trial in solid tumours
AstraZeneca and Eli Lilly and Company (Lilly) today announced that they have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ramucirumab (CYRAMZA®), Lilly’s VEGF Receptor 2 antiangiogenic cancer medicine. The planned study will assess the combination as
-
AstraZeneca provides update on brodalumab development programme
Amgen today announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
-
AstraZeneca investerar i ny anläggning i Södertälje för tillverkning av biologiska läkemedel
AstraZeneca meddelar i dag sina planer på att investera cirka 285 miljoner USD i en ny högteknologisk anläggning för tillverkning av biologiska läkemedel i Gärtuna utanför Södertälje. Den nya anläggningen kommer fokusera på fyllning och packning av proteinläkemedel. Det förväntas att den nya enheten kommer att producera läkemedel till kliniska prövningsprogram för AstraZeneca och Medimmune, koncer
-
AstraZeneca to update on progress with Immuno-Oncology pipeline and combination treatments at ASCO 2015
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May-2 June 2015
-
AstraZeneca and Abbott to develop companion diagnostic tests for tralokinumab in severe asthma
AstraZeneca today announced that it has entered an agreement with Abbott, a global healthcare company, to develop companion diagnostic tests to identify patients with severe asthma who are most likely to benefit from the investigational biological therapy, tralokinumab.
-
AstraZeneca and Montreal Heart Institute to screen 80,000 samples for cardiovascular and diabetes genetic traits
AstraZeneca today announced a collaboration with the Montreal Heart Institute (MHI) in Quebec, Canada, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes.
-
Svenska Lungcancerstudiegruppen (SLUSG) delar ut stipendium
Idag tilldelas Leg.läk. Professor Rolf Lewensohn, verksam vid Karolinska Institutet och Överläkare vid Onkologiska kliniken Karolinska Universitetssjukhuset i Stockholm, SLUSG-stipendiet 2015.
-
US FDA grants Priority Review for potential new indication for BRILINTA
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) and granted Priority Review for BRILINTA® (ticagrelor) tablets for patients with a history of heart attack. The sNDA is based on the results of the PEGASUS-TIMI 54 study, a large-scale outcomes trial in more than 21,000 patients that investigated ticagrelor tablets plu
-
Positive phase III results for two antibiotics, ZINFORO™ and investigational ceftazidime-avibactam, presented at leading Infectious Diseases Conference
Encouraging new data of relevance to Global public health crisis, presented at 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
-
AstraZeneca PLC: Delårsrapport för första kvartalet 2015 - sammanfattning. Bifogat finns den fullständiga rapporten
Det finansiella resultatet för kvartal 1 2015 ger stöd åt upprepad helårsprognos för 2015.
oTotala intäkter (definierat som produktförsäljning och intäkter från externa samarbeten1) ökade med 1% i fasta valutakurser 2 (CER) till 6 057 MUSD (Q1 2014: 6 460 MUSD)
oVinst per aktie för kärnverksamheten (Core EPS) minskade med 3% till1,08 USD i takt med att vi fortsätter att investera i att uppn -
AstraZeneca enters strategic immuno-oncology collaboration with Celgene Corporation to develop PD-L1 inhibitor programme for patients with serious blood cancers
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into an exclusive collaboration agreement with Celgene Corporation, a global leader in haematological cancers, for the development and commercialisation of MEDI4736
-
AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into a collaboration to accelerate and broaden the development of Innate Pharma SA’s proprietary anti-NKG2A antibody
Visa mer
Loading...